Drug Discov Today . SARS-CoV-2-mediated hyperferritinemia and cardiac arrest: preliminary insights

[tetano]

Drug Discov Today


. 2021 Jan 22;S1359-6446(21)00041-6.
doi: 10.1016/j.drudis.2021.01.014. Online ahead of print.
SARS-CoV-2-mediated hyperferritinemia and cardiac arrest: preliminary insights


Prakash VasanthiDharmalingam ¹ , Vengadeshprabhu Karuppagounder ² , Kenichi Watanabe ³ , Harry Karmouty-Quintana ⁴ , Suresh S Palaniyandi ⁵ , Ashrith Guha ⁶ , Rajarajan A Thandavarayan ⁷



Affiliations

• PMID: 33493677
• DOI: 10.1016/j.drudis.2021.01.014

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a pandemic that began in China, was first noted in December 2019 {AuQ: Edit OK?}. SARS-CoV-2 infects through the angiotensin-converting enzyme-2 (ACE-2) receptor and co-receptors. In the most severely affected patients, it can cause {AuQ: Edit OK?} pneumonia and multiple organ failure leading to death. Reports describe high death rates resulting from cardiac dysfunction, a co-morbid condition in SARS-CoV-2 patients, while the primary cause and mechanisms remain unknown. Here, we attempt to review clinical reports of SARS-CoV-2 patients in order to provide insight into a possible mechanism that allows hyperferritinemia (the presence of excess iron-binding protein) to cause cardiac dysfunction in SARS-CoV-2 patients. Such insights are an important avenue towards understanding the mechanism of cardiac dysfunction in SARS-CoV-2 patients and developing remedies for the same.